Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) EBITDA: 2010-2025

Historic EBITDA for Ligand Pharmaceuticals (LGND) over the last 16 years, with Sep 2025 value amounting to $54.9 million.

  • Ligand Pharmaceuticals' EBITDA rose 1647.73% to $54.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 million, marking a year-over-year increase of 207.32%. This contributed to the annual value of -$22.6 million for FY2024, which is 289.30% down from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported EBITDA of $54.9 million as of Q3 2025, which was up 550.53% from $8.4 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' EBITDA registered a high of $54.9 million during Q3 2025, and its lowest value of -$36.2 million during Q1 2025.
  • Moreover, its 3-year median value for EBITDA was $3.0 million (2024), whereas its average is $1.5 million.
  • Data for Ligand Pharmaceuticals' EBITDA shows a peak YoY increase of 1,647.73% (in 2025) and a maximum YoY decrease of 1,312.05% (in 2025) over the last 5 years.
  • Over the past 5 years, Ligand Pharmaceuticals' EBITDA (Quarterly) stood at $37.7 million in 2021, then crashed by 153.33% to -$20.1 million in 2022, then spiked by 83.29% to -$3.4 million in 2023, then tumbled by 186.99% to -$9.6 million in 2024, then skyrocketed by 1,647.73% to $54.9 million in 2025.
  • Its EBITDA was $54.9 million in Q3 2025, compared to $8.4 million in Q2 2025 and -$36.2 million in Q1 2025.